Casey Mulligan, Ph.D., professor of economics at the University of Chicago, member of the National Bureau of Economic Research (NBER), and former Chief Economist of the White House Council of Economic Advisers, testified before the U.S. Senate Committee on Commerce, Science, and Transportation during a hearing Thursday on S. 127.
Unlocking an Affordable Future: Key #1 Ensure System Sustainability ENSURE SYSTEM SUSTAINABILITY BY PROMOTING COMPETITION A competitive private market is the best way to manage drug costs. Interventions should be focused on fixing specific market failures or gaps rather than
With a nod to Dickens given that it’s the holidays, I’ve been thinking about biosimilars past, present and future lately. In that holiday spirit, even though the parallels aren’t perfect to the classic holiday story, let’s look at the biosimilar
PBMs Reduce Insulin Costs PBMs are working to improve the lives of patients living with diabetes and their families Insulin prices are high because there are only a few insulin manufacturers, shielded from competition, and those companies set and raise
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
PBMs: Committed to Helping Patients The Critical Path Forward: Rx Policies to Reduce Patient Costs, Improve Access For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans. But more can
The Medicare Prescription Drug Rebate Rule The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate rule clumsily attempts to eliminate the primary tool used by
According to a new analysis, there are now 70 PBMs operating in a diverse and competitive marketplace.
©2024 PCMA. All Rights Reserved.
